US7763615 — Ecteinascidin analogs for use as antitumour agents
Method of Use · Assigned to Pharmamar SA · Expires 2029-12-13 · 4y remaining
What this patent protects
This patent protects a class of ecteinascidin analogs as antitumor agents.
USPTO Abstract
Derivatives of ecteinascidin 736 of general formula (I) wherein the groups R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of H, OH, ORâ², SH, SRâ², SORâ², SO 2 Râ², C(âO)Râ², C(âO)ORâ², NO 2 , NH 2 , NHRâ², N(Râ²) 2 , NHC(O)Râ², CN, halogen, âO, substituted or unsubstituted C 1 -C 25 alkyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic; wherein X is independently selected of ORâ², CN, (âO), or H; wherein each of the Râ² groups is independently selected from the group consisting of H, OH, NO 2 , NH 2 , SH, CN, halogen, âO, C(âO)H, C(âO)CH 3 , CO 2 H, substituted or unsubstituted C 1 -C 25 alkyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl; wherein m is 0, 1 or 2; and wherein n is 0, 1, 2, 3, or 4, and their use as antitumoral agent.
Drugs covered by this patent
- Zepzelca (LURBINECTEDIN) · Jazz Pharmaceuticals
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4299 |
— | Zepzelca |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.